JP2018528946A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528946A5 JP2018528946A5 JP2018510334A JP2018510334A JP2018528946A5 JP 2018528946 A5 JP2018528946 A5 JP 2018528946A5 JP 2018510334 A JP2018510334 A JP 2018510334A JP 2018510334 A JP2018510334 A JP 2018510334A JP 2018528946 A5 JP2018528946 A5 JP 2018528946A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- halo
- substituted
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 78
- 229910052739 hydrogen Inorganic materials 0.000 claims 53
- 239000001257 hydrogen Substances 0.000 claims 53
- 150000001875 compounds Chemical class 0.000 claims 38
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 35
- 125000005843 halogen group Chemical group 0.000 claims 27
- 229910052757 nitrogen Inorganic materials 0.000 claims 23
- 125000001424 substituent group Chemical group 0.000 claims 21
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000002619 bicyclic group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 206010052779 Transplant rejections Diseases 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000034486 Multi-organ failure Diseases 0.000 claims 2
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000019100 sperm motility Effects 0.000 claims 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 2
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021120042A JP7720732B2 (ja) | 2015-08-26 | 2021-07-20 | Ｐｒｍｔ５阻害剤として使用するための新規な６－６二環式芳香環置換ヌクレオシド類似体 |
| JP2023184701A JP2024012405A (ja) | 2015-08-26 | 2023-10-27 | Ｐｒｍｔ５阻害剤として使用するための新規な６－６二環式芳香環置換ヌクレオシド類似体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562209941P | 2015-08-26 | 2015-08-26 | |
| US62/209,941 | 2015-08-26 | ||
| EP15184011.3 | 2015-09-07 | ||
| EP15184011 | 2015-09-07 | ||
| US201662306233P | 2016-03-10 | 2016-03-10 | |
| US62/306,233 | 2016-03-10 | ||
| PCT/EP2016/070097 WO2017032840A1 (en) | 2015-08-26 | 2016-08-25 | Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021120042A Division JP7720732B2 (ja) | 2015-08-26 | 2021-07-20 | Ｐｒｍｔ５阻害剤として使用するための新規な６－６二環式芳香環置換ヌクレオシド類似体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018528946A JP2018528946A (ja) | 2018-10-04 |
| JP2018528946A5 true JP2018528946A5 (enExample) | 2019-10-24 |
| JP6917978B2 JP6917978B2 (ja) | 2021-08-11 |
Family
ID=54065259
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510334A Active JP6917978B2 (ja) | 2015-08-26 | 2016-08-25 | Ｐｒｍｔ５阻害剤として使用するための新規な６−６二環式芳香環置換ヌクレオシド類似体 |
| JP2021120042A Active JP7720732B2 (ja) | 2015-08-26 | 2021-07-20 | Ｐｒｍｔ５阻害剤として使用するための新規な６－６二環式芳香環置換ヌクレオシド類似体 |
| JP2023184701A Withdrawn JP2024012405A (ja) | 2015-08-26 | 2023-10-27 | Ｐｒｍｔ５阻害剤として使用するための新規な６－６二環式芳香環置換ヌクレオシド類似体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021120042A Active JP7720732B2 (ja) | 2015-08-26 | 2021-07-20 | Ｐｒｍｔ５阻害剤として使用するための新規な６－６二環式芳香環置換ヌクレオシド類似体 |
| JP2023184701A Withdrawn JP2024012405A (ja) | 2015-08-26 | 2023-10-27 | Ｐｒｍｔ５阻害剤として使用するための新規な６－６二環式芳香環置換ヌクレオシド類似体 |
Country Status (35)
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI870767B (zh) | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| MX374813B (es) * | 2016-03-10 | 2025-03-06 | Janssen Pharmaceutica Nv | Análogos de nucleósidos sustituidos para su uso como inhibidores de prmt5. |
| CA2969295A1 (en) * | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| AU2017326487B2 (en) | 2016-09-14 | 2021-08-05 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| US10611778B2 (en) | 2016-09-14 | 2020-04-07 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-MLL interaction |
| JP7101171B2 (ja) | 2016-10-03 | 2022-07-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体 |
| BR112019012106A2 (pt) | 2016-12-15 | 2019-10-29 | Janssen Pharmaceutica Nv | inibidores de azepano de interação menin-mill |
| GB201700526D0 (en) * | 2017-01-12 | 2017-03-01 | Univ Of Hull | Therapeutic use |
| EA201990851A1 (ru) | 2017-02-24 | 2019-09-30 | Янссен Фармацевтика Нв | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 |
| JP7225106B2 (ja) | 2017-02-27 | 2023-02-20 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐｒｍｔ５阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用 |
| BR112020002736A2 (pt) | 2017-08-09 | 2020-07-28 | Prelude Therapeutics, Incorporated | inibidores seletivos da proteína arginina metiltransferase 5 (prmt5) |
| US11524962B2 (en) | 2017-10-26 | 2022-12-13 | Prelude Therapeutics, Incorporated | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5) |
| WO2019112719A1 (en) * | 2017-12-05 | 2019-06-13 | Angex Pharmaceutical, Inc. | Heterocyclic compounds as prmt5 inhibitors |
| MA51004A (fr) * | 2017-12-08 | 2020-10-14 | Janssen Pharmaceutica Nv | Nouveaux analogues spirobicycliques |
| UA126349C2 (uk) * | 2017-12-13 | 2022-09-21 | Люпін Лімітед | Заміщені біциклічні гетероциклічні сполуки як інгібітори prmt5 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| DK3765461T3 (da) * | 2018-03-14 | 2023-11-20 | Prelude Therapeutics Inc | Selektive protein argininmethyltransferase 5 (prmt5)-hæmmere |
| US10711007B2 (en) | 2018-03-14 | 2020-07-14 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
| EP3833668B1 (en) * | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| WO2020033288A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US11981701B2 (en) | 2018-08-07 | 2024-05-14 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| WO2020033285A1 (en) * | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| US12435088B2 (en) | 2018-12-21 | 2025-10-07 | Memorial Sloan-Kettering Cancer Center | Salicyl-adenosinemonosulfamate analogs and uses thereof |
| CN109400545B (zh) * | 2018-12-24 | 2022-03-25 | 济南大学 | 一种精氨酸甲基转移酶5抑制剂及其应用 |
| CN109369507A (zh) * | 2018-12-26 | 2019-02-22 | 重庆市碚圣医药科技股份有限公司 | 一种n-(2,2-二乙氧基乙基)邻苯二甲酰亚胺的提纯方法 |
| BR112021015796A2 (pt) * | 2019-02-13 | 2021-10-13 | Prelude Therapeutics, Incorporated | Inibidor seletivo de proteína arginina metiltransferase 5 (prmt5) |
| EP3939988A4 (en) * | 2019-03-20 | 2022-08-24 | Korea Research Institute of Chemical Technology | Pharmaceutical composition comprising novel azolopyrimidine heterocyclic compound as active ingredient |
| IL318073A (en) * | 2019-03-25 | 2025-02-01 | California Inst Of Techn | PRMT5 inhibitors and their uses |
| US11198699B2 (en) | 2019-04-02 | 2021-12-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
| EP3952874A4 (en) * | 2019-04-05 | 2022-12-28 | Prelude Therapeutics, Incorporated | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 |
| EP3946352A4 (en) * | 2019-04-05 | 2022-12-28 | Prelude Therapeutics, Incorporated | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 |
| CA3141855A1 (en) * | 2019-05-30 | 2020-12-03 | Angex Pharmaceutical, Inc. | Heterocyclic compounds as prmt5 inhibitors |
| TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用ｐｒｍｔ５抑制劑治療癌症之方法 |
| US12391695B2 (en) * | 2019-06-10 | 2025-08-19 | Lupin Limited | PRMT5 inhibitors |
| EP3983393B1 (en) | 2019-06-12 | 2025-04-02 | Janssen Pharmaceutica NV | Novel spirobicyclic intermediates |
| KR20220065811A (ko) * | 2019-09-18 | 2022-05-20 | 프렐루드 테라퓨틱스, 인코포레이티드 | 단백질 아르기닌 메틸트랜스퍼라제 5(prmt5)의 선택적 억제제 |
| EP4048674A2 (en) * | 2019-10-21 | 2022-08-31 | Accent Therapeutics, Inc. | Mettl3 modulators |
| KR20220086628A (ko) * | 2019-10-22 | 2022-06-23 | 루핀 리미티드 | Prmt5 저해제의 약학적 조합물 |
| GB201915447D0 (en) * | 2019-10-24 | 2019-12-11 | Johnson Matthey Plc | Polymorphs of avapritinib and methods of preparing the polymorphs |
| WO2021111322A1 (en) | 2019-12-03 | 2021-06-10 | Lupin Limited | Substituted nucleoside analogs as prmt5 inhibitors |
| WO2021126729A1 (en) | 2019-12-17 | 2021-06-24 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| IL293965A (en) | 2019-12-19 | 2022-08-01 | Janssen Pharmaceutica Nv | History of Spiro straight chain transformed |
| TWI883391B (zh) | 2020-02-18 | 2025-05-11 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| AU2021224588B2 (en) | 2020-02-18 | 2024-07-18 | Gilead Sciences, Inc. | Antiviral compounds |
| CN111233869B (zh) * | 2020-03-12 | 2022-09-16 | 杭州新博思生物医药有限公司 | 用于制备瑞德西韦关键中间体的新化合物及其制备方法 |
| WO2021202480A1 (en) * | 2020-04-01 | 2021-10-07 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
| US20240101589A1 (en) * | 2020-10-08 | 2024-03-28 | Strom Therapeutics Limited | Inhibitors of mettl3 |
| CN112645875A (zh) * | 2020-12-09 | 2021-04-13 | 深圳海王医药科技研究院有限公司 | 一种盐酸丙卡特罗杂质的制备方法 |
| KR20230170745A (ko) | 2021-04-16 | 2023-12-19 | 길리애드 사이언시즈, 인코포레이티드 | 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법 |
| CN113234079B (zh) * | 2021-04-30 | 2022-02-01 | 上海湃隆生物科技有限公司 | 用作prmt5抑制剂的核苷类似物 |
| CN117157297A (zh) * | 2021-07-20 | 2023-12-01 | 上海齐鲁制药研究中心有限公司 | Prmt5抑制剂 |
| CN115703796A (zh) * | 2021-08-09 | 2023-02-17 | 苏州恩泰新材料科技有限公司 | 一种瑞德西韦重要中间体制备方法 |
| US12116380B2 (en) | 2021-08-18 | 2024-10-15 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| GB202117230D0 (en) | 2021-11-29 | 2022-01-12 | Argonaut Therapeutics Ltd | Peptide vaccine |
| GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
| CN116655638B (zh) * | 2022-05-12 | 2024-01-26 | 上海齐鲁制药研究中心有限公司 | 氘代prmt5抑制剂 |
| CN116003339B (zh) * | 2022-12-01 | 2024-06-28 | 南京师范大学 | 一种巨噬细胞迁移抑制因子mif双光子荧光探针及其制备方法和应用 |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| EP4553080A1 (en) | 2023-11-07 | 2025-05-14 | Ustav Organicke Chemie a Biochemie AV CR, v.v.i. | Nucleoside derivatives as antiviral agents against coronaviruses |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4224438A (en) | 1970-07-14 | 1980-09-23 | Boehringer Mannheim Gmbh | Adenosine-5'-carboxylic acid amides |
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| AU2002351077A1 (en) | 2001-11-05 | 2003-05-19 | Exiqon A/S | Oligonucleotides modified with novel alpha-l-rna analogues |
| US7034147B2 (en) | 2001-11-29 | 2006-04-25 | Irm Llc | Nucleoside analog libraries |
| EP1476455A1 (en) * | 2002-02-19 | 2004-11-17 | Cv Therapeutics, Inc. | PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS |
| US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| TWI265376B (en) * | 2002-03-20 | 2006-11-01 | Sumitomo Chemical Co | Positive resist composition |
| AU2002951247A0 (en) * | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| US20060167241A1 (en) | 2003-07-15 | 2006-07-27 | Mitsui Chemicals, Inc. | Method for synthesizing cyclic bisdinucleoside |
| CA2548283A1 (en) | 2003-12-19 | 2005-07-21 | Koronis Pharmaceuticals, Inc. | Mutagenic heterocycles |
| EP1844062A2 (en) | 2005-01-21 | 2007-10-17 | Methylgene, Inc. | Inhibitors of dna methyltransferase |
| US20110159111A1 (en) | 2006-06-29 | 2011-06-30 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
| US8962580B2 (en) | 2008-09-23 | 2015-02-24 | Alnylam Pharmaceuticals, Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| EP2513298A4 (en) | 2009-12-18 | 2013-03-27 | Harvard College | BETAZELLEN REPLICATION FOR PROMOTER CONNECTIONS AND USE METHOD THEREFOR |
| CA2819620A1 (en) | 2010-12-03 | 2012-06-21 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| CA2819625A1 (en) | 2010-12-03 | 2012-06-07 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| JP5906253B2 (ja) | 2010-12-16 | 2016-04-20 | アッヴィ・インコーポレイテッド | 抗ウイルス性化合物 |
| EP2694524B1 (en) | 2011-04-04 | 2016-05-18 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | 2'-o-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides |
| US20140357594A1 (en) | 2011-10-24 | 2014-12-04 | Glaxosmithkline Intellectual Property (No.2) Limited | New compounds |
| US20150057243A1 (en) | 2012-04-02 | 2015-02-26 | Northern University | Compositions and Methods for the Inhibition of Methyltransferases |
| WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
| US20140100184A1 (en) | 2012-08-31 | 2014-04-10 | Baylor College Of Medicine | Selective inhibitors of histone methyltransferase dot1l |
| JP2016505000A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| MY199894A (en) | 2012-12-21 | 2023-11-27 | Epizyme Inc | Prmt5 inhibitors and uses thereof |
| WO2014100716A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| JP2016505002A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用 |
| WO2014145214A2 (en) | 2013-03-15 | 2014-09-18 | Ohio State Innovation Foundation | Inhibitors of prmt5 and methods of their use |
| US10087151B2 (en) | 2014-01-09 | 2018-10-02 | The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone | Substituted benzoxazine and related compounds |
| US20170198006A1 (en) | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| RS59474B1 (sr) | 2014-07-01 | 2019-12-31 | Millennium Pharm Inc | Heteroarilna jedinjenja koja su korisna kao inhibitori sumo-aktivirajućeg enzima |
| TN2017000357A1 (en) | 2015-02-24 | 2019-01-16 | Pfizer | Substituted nucleoside derivatives useful as anticancer agents |
| TWI870767B (zh) * | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| AU2017230658B2 (en) | 2016-03-10 | 2021-03-04 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as PRMT5 inhibitors |
| JP7101171B2 (ja) * | 2016-10-03 | 2022-07-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐｒｍｔ５阻害剤として使用するための新規な単環式および二環式環系置換カルバヌクレオシド類似体 |
| EA201990851A1 (ru) | 2017-02-24 | 2019-09-30 | Янссен Фармацевтика Нв | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 |
| JP7225106B2 (ja) | 2017-02-27 | 2023-02-20 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐｒｍｔ５阻害剤による治療に応答する癌患者の同定におけるバイオマーカーの使用 |
| MA51004A (fr) | 2017-12-08 | 2020-10-14 | Janssen Pharmaceutica Nv | Nouveaux analogues spirobicycliques |
-
2016
- 2016-08-24 TW TW112102610A patent/TWI870767B/zh active
- 2016-08-24 TW TW105126988A patent/TWI730980B/zh active
- 2016-08-24 TW TW110127686A patent/TWI791251B/zh active
- 2016-08-25 LT LTEPPCT/EP2016/070097T patent/LT3341368T/lt unknown
- 2016-08-25 MY MYPI2018000274A patent/MY198472A/en unknown
- 2016-08-25 CA CA2992688A patent/CA2992688A1/en active Pending
- 2016-08-25 MA MA42678A patent/MA42678B1/fr unknown
- 2016-08-25 PL PL16757233T patent/PL3341368T3/pl unknown
- 2016-08-25 IL IL311843A patent/IL311843A/en unknown
- 2016-08-25 BR BR112018003595-5A patent/BR112018003595B1/pt active IP Right Grant
- 2016-08-25 PE PE2022000450A patent/PE20221629A1/es unknown
- 2016-08-25 EP EP21199207.8A patent/EP3974428A1/en active Pending
- 2016-08-25 MX MX2018002326A patent/MX392554B/es unknown
- 2016-08-25 PT PT167572338T patent/PT3341368T/pt unknown
- 2016-08-25 SI SI201631402T patent/SI3341368T1/sl unknown
- 2016-08-25 HU HUE16757233A patent/HUE057312T2/hu unknown
- 2016-08-25 NZ NZ779003A patent/NZ779003A/en unknown
- 2016-08-25 BR BR122023020317-8A patent/BR122023020317A2/pt not_active Application Discontinuation
- 2016-08-25 NZ NZ740528A patent/NZ740528A/en unknown
- 2016-08-25 RS RS20211526A patent/RS62698B1/sr unknown
- 2016-08-25 EP EP16757233.8A patent/EP3341368B1/en active Active
- 2016-08-25 HR HRP20211997TT patent/HRP20211997T1/hr unknown
- 2016-08-25 ES ES16757233T patent/ES2901972T3/es active Active
- 2016-08-25 CN CN202111120182.2A patent/CN114057815B/zh active Active
- 2016-08-25 SM SM20210725T patent/SMT202100725T1/it unknown
- 2016-08-25 KR KR1020187007810A patent/KR102716092B1/ko active Active
- 2016-08-25 SG SG10202003775VA patent/SG10202003775VA/en unknown
- 2016-08-25 CN CN201680048987.1A patent/CN107922413B/zh active Active
- 2016-08-25 PE PE2018000306A patent/PE20180929A1/es unknown
- 2016-08-25 JP JP2018510334A patent/JP6917978B2/ja active Active
- 2016-08-25 EA EA201890573A patent/EA201890573A1/ru unknown
- 2016-08-25 AU AU2016311295A patent/AU2016311295B2/en active Active
- 2016-08-25 EP EP23162887.6A patent/EP4219496A1/en active Pending
- 2016-08-25 PH PH1/2018/500425A patent/PH12018500425B1/en unknown
- 2016-08-25 AR ARP160102600A patent/AR105820A1/es active IP Right Grant
- 2016-08-25 MD MDE20180642T patent/MD3341368T2/ro unknown
- 2016-08-25 PH PH1/2021/552054A patent/PH12021552054A1/en unknown
- 2016-08-25 US US15/755,475 patent/US10653711B2/en active Active
- 2016-08-25 TN TNP/2018/000043A patent/TN2018000043A1/en unknown
- 2016-08-25 DK DK16757233.8T patent/DK3341368T3/da active
- 2016-08-25 WO PCT/EP2016/070097 patent/WO2017032840A1/en not_active Ceased
-
2018
- 2018-02-21 IL IL257664A patent/IL257664B/en active IP Right Grant
- 2018-02-23 MX MX2022005182A patent/MX2022005182A/es unknown
- 2018-02-26 CL CL2018000510A patent/CL2018000510A1/es unknown
- 2018-02-26 CO CONC2018/0002063A patent/CO2018002063A2/es unknown
-
2020
- 2020-03-20 US US16/825,024 patent/US11318157B2/en active Active
-
2021
- 2021-01-20 AU AU2021200345A patent/AU2021200345B2/en active Active
- 2021-04-21 IL IL282537A patent/IL282537A/en unknown
- 2021-07-20 JP JP2021120042A patent/JP7720732B2/ja active Active
-
2022
- 2022-01-04 CY CY20221100008T patent/CY1125359T1/el unknown
- 2022-03-09 US US17/690,587 patent/US11883367B2/en active Active
- 2022-08-11 AU AU2022215260A patent/AU2022215260B2/en active Active
-
2023
- 2023-03-21 US US18/187,463 patent/US20230330127A1/en not_active Abandoned
- 2023-10-27 JP JP2023184701A patent/JP2024012405A/ja not_active Withdrawn
-
2024
- 2024-03-28 AU AU2024202052A patent/AU2024202052A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528946A5 (enExample) | ||
| JP2022084699A5 (enExample) | ||
| JP2019532031A5 (enExample) | ||
| JP2019518059A5 (enExample) | ||
| RU2309946C2 (ru) | Новые соединения в качестве противовоспалительных, иммуномодулирующих и противопролиферативных агентов | |
| HRP20211997T1 (hr) | Novi supstituirani nukleozidni analozi 6-6 bicikličkog aromatskog prstena za upotrebu kao inhibitori prmt5 | |
| JP2018535199A5 (enExample) | ||
| JP2018519302A5 (enExample) | ||
| RU2013142448A (ru) | Новые сульфонаминохинолиновые антагонисты гепсидина | |
| JP2018536648A5 (enExample) | ||
| JP2019501130A5 (enExample) | ||
| HRP20221207T1 (hr) | Supstituirani biciklički heterociklički spojevi kao inhibitori prmt5 | |
| JP2014513110A5 (enExample) | ||
| JP2011521911A5 (enExample) | ||
| JP2021502387A5 (enExample) | ||
| JP2015514808A5 (enExample) | ||
| JP2013532652A5 (enExample) | ||
| IL275129B2 (en) | Novel spirobicyclic analogues | |
| EA201391558A1 (ru) | Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения | |
| JP2007538024A5 (enExample) | ||
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| JP2013542261A5 (enExample) | ||
| AR094272A1 (es) | Compuestos de diona ciclica activos como herbicidas, o derivados de los mismos, sustituidos por un fenilo que tiene un sustituyente que contiene alquinilo | |
| JP2016503778A5 (enExample) | ||
| JP2020500866A5 (enExample) |